CLINICAL TRIALS PROFILE FOR HORIZANT
✉ Email this page to a colleague
All Clinical Trials for Horizant
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01533753 ↗ | Quality of Life Study Using Gabapentin Versus Venlafaxine in Treating Hot Flashes in Patients With Prostate Cancer | Terminated | University of Wisconsin, Madison | Phase 2 | 2012-02-01 | The purpose of this study is to assess the change in quality of life over a 6 month period between gabapentin and venlafaxine in men with prostate cancer treated for hot flashes related to androgen deprivation therapy. |
| NCT01668667 ↗ | Gabapentin Enacarbil (GSK1838262) Adult Restless Leg Syndrome (RLS) Post Marketing Commitment Study | Completed | XenoPort, Inc. | Phase 4 | 2012-06-01 | Gabapentin enacarbil (GEn; GSK1838262; HORIZANT), at a dose of 600 mg/day, is currently approved in the United States for the treatment of adults with moderate-to-severe primary Restless Legs Syndrome (RLS). The aim of this study is to compare the efficacy, tolerability, and safety of GEn at lower doses (450 and 300 mg/day) as well as the already approved dose of 600 mg/day versus placebo for the treatment of subjects with moderate to severe primary RLS. This study is being conducted as a post-marketing commitment (PMC) as a condition of the approval of HORIZANT tablets (NDA 022399). |
| NCT01675960 ↗ | Effectiveness of Gabapentin on Chronic Irritability in Neurologically Impaired Children | Terminated | Gillette Children's Specialty Healthcare | Phase 2 | 2012-04-01 | This study is a prospective, randomized, double blind, placebo controlled, crossover clinical trial looking at whether gabapentin can provide symptom relief for chronic irritability in neurologically impaired children. The investigators hypothesize gabapentin ins beneficial and safe for children with chronic irritability that persists despite identification and appropriate management of symptom sources. |
| NCT01675960 ↗ | Effectiveness of Gabapentin on Chronic Irritability in Neurologically Impaired Children | Terminated | Scott Schwantes, M.D. | Phase 2 | 2012-04-01 | This study is a prospective, randomized, double blind, placebo controlled, crossover clinical trial looking at whether gabapentin can provide symptom relief for chronic irritability in neurologically impaired children. The investigators hypothesize gabapentin ins beneficial and safe for children with chronic irritability that persists despite identification and appropriate management of symptom sources. |
| NCT01680549 ↗ | Pain Control With Total Knee Replacement | Completed | Texas Tech University Health Sciences Center | Phase 4 | 2012-09-01 | The purpose of this project is to study the effects of gabapentin on pain control in the perioperative and post-operative period of total knee arthroplasty. |
| NCT02117076 ↗ | Blinded, Randomized Study of Gabapentin (Neurontin®) and Gabapentin Enacarbil (Horizant™) in Restless Leg Syndrome | Terminated | Theresa Zesiewicz | Phase 4 | 2014-04-01 | The study will compare the safety, effectiveness and tolerability of gabapentin (Neurontin) versus gabapentin enacarbil (Horizant) as treatment restless leg syndrome. |
| NCT02252536 ↗ | HORIZANT (Gabapentin Enacarbil Extended-Release Tablets) for the Treatment of Alcohol Use Disorder | Completed | Arbor Pharmaceuticals, Inc. | Phase 2 | 2015-06-01 | The purpose of this study is to determine whether gabapentin enacarbil is effective in the treatment of problems with alcohol. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Horizant
Condition Name
Clinical Trial Locations for Horizant
Trials by Country
Clinical Trial Progress for Horizant
Clinical Trial Phase
Clinical Trial Sponsors for Horizant
Sponsor Name
